About Asuragen
Asuragen is a company based in Austin (United States) founded in 2006 was acquired by Bio-Techne in March 2021. Asuragen has raised $80 million across 23 funding rounds from investors including Bio-Techne, HHS and PTV Healthcare Capital. Asuragen operates in a competitive market with competitors including Guardant Health, Abcam, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Asuragen, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$80 M (USD)
in 23 rounds
-
Latest Funding Round
$182.39 K (USD), Grant
Sep 30, 2019
-
Investors
Bio-Techne
& 4 more
-
Employee Count
Not available
-
Acquired by
Bio-Techne
(Mar 03, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Asuragen
Unlock access to complete
Software Development Team
92 people
Sales and Marketing
76 people
Leadership Team
40 people
Product Management Team
35 people
Senior Team
31 people
Finance and Accounting
20 people
Human Resources and Administration
18 people
Advanced Team
13 people
Unlock access to complete
Funding Insights of Asuragen
Asuragen has successfully raised a total of $80M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $182.39 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Asuragen
Asuragen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Bio-Techne, HHS and PTV Healthcare Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science, medical device and healthcare companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in expansion & late stage start-ups in the US
|
Locked | Locked | Locked |
Investor details for Asuragen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Asuragen
Investment portfolio details for Asuragen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Asuragen
Detailed financials for Asuragen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Asuragen Comparisons
Peer comparison for Asuragen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Asuragen
Asuragen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Abcam, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Asuragen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Asuragen
Complete news archive for Asuragen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Asuragen
Asuragen was founded in 2006.
Asuragen is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Asuragen is a funded company, having raised a total of $80M across 23 funding rounds to date.
Asuragen was founded in 2006 in Austin, United States, as a provider of molecular diagnostics in genetics and oncology. Kits for genetic sequencing and cancer monitoring are offered, including AmplideX reagents for FMR1 gene analysis and Quantidex products for lung cancer and chronic myeloid leukemia quantification. FDA clearance has been obtained for several products, supporting research and clinical applications in the sector.
Asuragen's top competitors include Guardant Health, Abcam and Foundation Medicine.
Asuragen has 5 investors. Key investors include Bio-Techne, HHS, PTV Healthcare Capital, Telegraph Hill Partners, and Growth Capital Fund.